Showing results (391-400 of 722) with videos related to

Sort By:
Pageof 73
The Lancet. Haematology|March 16, 2025
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 studyHasmukh Jain, Atharva Karulkar, Devanshi Kalra, et al.
The Lancet. Haematology|November 21, 2017
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot studyBerend Snijder, Gregory I Vladimer, Nikolaus Krall, et al.
The Lancet. Haematology|December 4, 2018
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 studyKieron Dunleavy, Michelle A Fanale, Jeremy S Abramson, et al.
The Lancet. Haematology|December 19, 2018
Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysisGhadeer K Dawwas, Joshua Brown, Eric Dietrich, et al.
The Lancet. Haematology|February 11, 2019
A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation studyGordon Cook, Kara-Louise Royle, Charlotte Pawlyn, et al.
The Lancet. Haematology|December 9, 2017
Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trialArina J Ten Cate-Hoek, Elham E Amin, Annemieke C Bouman, et al.
The Lancet. Haematology|December 16, 2017
Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trialMoshe Mittelman, Uwe Platzbecker, Boris Afanasyev, et al.
The Lancet. Haematology|February 2, 2019
Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 studyNoelle Frey, Jun Ho Jang, Jeff Szer, et al.
The Lancet. Haematology|February 3, 2019
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trialLoretta J Nastoupil, Matthew A Lunning, Julie M Vose, et al.
The Lancet. Haematology|February 3, 2019
Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational studyClare White, Simon I R Noble, Max Watson, et al.
Pageof 73